NCT02302443View on ClinicalTrials.gov

A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM12470

PHASE1CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

May 31, 2017

Study Completion Date

May 31, 2017

Conditions
Diabetes Mellitus
Interventions
BIOLOGICAL

HM12470

Single dose subcutaneous administration ranging from a very low dose to high dose

BIOLOGICAL

Active comparator

Single dose subcutaneous administration of active comparator

Trial Locations (1)

Unknown

Hanmi Pharmaceutical Company, Seoul

Sponsors
All Listed Sponsors
lead

Hanmi Pharmaceutical Company Limited

INDUSTRY

NCT02302443 - A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM12470 | Biotech Hunter | Biotech Hunter